Diphenyl diselenide exerts anxiolytic-like effect in Wistar rats: Putative roles of GABAA and 5HT receptors

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1508-1515

  Ghisleni, Gabriele ^a   Kazlauckas, Vanessa ^b   Both, Fernanda L ^b   Pagnussat, Natália ^b   Mioranzza, Sabrina ^b   Rocha, João Batista T ^a   Souza, Diogo O ^b   Porciúncula, Lisiane O ^b  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

5HT receptors; Anxiety; Diphenyl diselenide; Elevated plus maze; Open field arena

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BICUCULLINE; DIPHENYL DISELENIDE; KETANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RITANSERIN; SEROTONIN RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE COMPARISON; FOOTSHOCK; LEARNING; LOCOMOTION; MALE; MAZE TEST; MEMORY; NONHUMAN; OPEN FIELD BEHAVIOR; PSYCHOPHARMACOLOGY; RAT; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BENZENE DERIVATIVES; BICUCULLINE; DEFECATION; ELECTROSHOCK; EXPLORATORY BEHAVIOR; GABA ANTAGONISTS; KETANSERIN; MALE; ORGANOSELENIUM COMPOUNDS; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, GABA-A; RECEPTORS, SEROTONIN; RITANSERIN; SEROTONIN ANTAGONISTS;

EID: 47749114152     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.05.008     Document Type: Article

References (56)

1. Argyropoulos S.V., Sandford J.J., and Nutt D.J. The psychobiology of anxiolytic drug. Part 2: pharmacological treatments of anxiety. Pharmacol Ther 3 (2000) 213-227
2. Atack J.R. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Exp Opin Investig Drugs 14 (2005) 601-618
3. Barbosa N.B., Rocha J.B., Wondracek D.C., Perottoni J., Zeni G., and Nogueira C.W. Diphenyl diselenide reduces temporarily hyperglycemia: possible relationship with oxidative stress. Chem Biol Interact 163 (2006) 230-238
4. Barnes N.M., Cheng C.H., Costall B., Ge J., Kelly M.E., and Naylor R.J. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model. Eur J Pharmacol 218 (1992) 91-100
5. Beneytez M.E., López Rodrígues M.L., Rosado M.L., Morcillo M.J., Orensanz L., Fuentes J.A., et al. Preclinical pharmacology of B-20991, a 5-HT1A receptor agonist with anxiolytic activity. Eur J Pharmacol 344 (1998) 127-135
6. Benton D. Selenium intake, mood and other aspects of psychological functioning. Nutr Neurosci 5 (2001) 363-374
7. Benton D., and Cook R. The impact of selenium supplementation on mood. Biol Psychiatry 29 (1991) 1092-1098
8. Borges L.P., Nogueira C.W., Panatieri R.B., Rocha J.B.T., and Zeni G. Acute liver damage induced by 2-nitropropane in rats: effect of diphenyl diselenide on antioxidant defenses. Chem Biol Interact 160 (2006) 99-107
9. Breese R.G., Knapp J.D., and Moy S.S. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 26 (2002) 441-455
10. Brito V.B., Folmer V., Puntel G.O., Fachinetto R., Soares J.C., Zeni G., et al. Diphenyl diselenide and 2,3-dimercaptopropanol increase the PTZ-induced chemical seizure and mortality in mice. Brain Res Bull 68 (2006) 414-418
11. Cain D.P. Prior non-spatial pretraining eliminates sensorimotor disturbances and impairments in water maze learning caused by diazepam. Psychopharmacology 130 (1997) 313-319
12. Chen J., and Berry M.J. Selenium and selenoproteins in the brain and brain diseases. J Neurochem 86 (2003) 1-12
13. Clement Y., and Chapouthier G. Biological bases of anxiety. Neurosci Biobehav Rev 22 (1998) 623-633
14. Commissaris R.L., Harrington G.M., Ortiz A.M., and Altman H.J. Maudsley reactive and non-reactive rat strains: differential performance in a conflict task. Physiol Behav 38 (1986) 291-294
15. Davidson J.R. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 11 (2001) 46-50
16. Ferre P., Fernandez-Teruel A., Escorihuela R.M., Driscoll P., Corda M.G., Giorgi O., et al. Behavior of the Roman/Verh high- and low-avoidance rat lines in anxiety tests: relationship with defecation and self-grooming. Physiol Behav 58 (1995) 1209-1213
17. Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., et al. Eletrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73 (1996) 337-353
18. Ghisleni G., Porciúncula L.O., Cimarosti H., Rocha J.B.T., Salbego C.G., and Souza D.O. Diphenyl diselenide protects rat hippocampal slices submitted to oxygen-glucose deprivation and diminishes inducible nitric oxide synthase immunocontent. Brain Res 986 (2003) 196-199
19. Graeff F.G., Viana M.B., and Mora P.O. Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 21 (1997) 791-799
20. Griebel G. Variability in the effects of 5-HT-related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story?. Pol J Pharmacol 2 (1996) 129-136
21. Griebel G., Rodgers J.R., Perrault G., and Sanger D.J. Risk assessment behavior: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus maze test. Pharmacol Biochem Behav 57 (1997) 817-827
22. Griebel G., Perrault G., Letang V., Granger P., Avenet P., Schoermaker H., et al. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. Psychopharmacology 146 (1999) 205-213
23. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71 (2002) 533-554
24. Izquierdo I., Bevilaqua L.R.M., Rossato J.I., Bonini J.S., Medina J.H., and Cammarota M. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci 29 (2006) 496-505
25. Kaplan M. Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry 61 (2006) 388-389
26. Lal H., and Emmett-Oglesby M.W. Behavioral analogues of anxiety. Anim Models Neuropharmacol 22 (1983) 1423-1441
27. Machado M.S., Rosa R.M., Dantas A.S., Reolon G.K., Appelt H.R., Braga A.L., et al. An organic selenium compound attenuates apomorphine-induced stereotypy in mice. Neurosci Lett 410 (2006) 198-202
28. Maciel E.N., Bolzan R.C., Braga A.L., and Rocha J.B.T. Diphenyl diselenide and diphenyl ditelluride differentially affect δ-aminolevulinate dehydratase from liver, kidney, and brain of mice. J Biochem Mol Toxicol 14 (2000) 310-319
29. Meotti F.C., Borges V.C., Zeni G., Rocha J.B., and Nogueira C.W. Potential renal and hepatic toxicity of diphenyl diselenide, diphenyl ditelluride and Ebselen for rats and mice. Toxicol Lett 143 (2003) 9-16
30. Moretto M.B., Thomazi A.P., Godinho G., Roessler T.M., Nogueira C.W., Souza D.O., et al. Ebselen and diorganylchalcogenides decrease in vitro glutamate uptake by RAT brain slices: prevention by DTT and GSH. Toxicol In Vitro 4 (2007) 639-645
31. Morris H.V., Dawson G.R., Reynolds D.S., Atack J.R., and Stephens D.N. Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm. Eur J Neurosci 9 (2006) 2495-2504
32. Nogueira C.W., Rotta L.N., Perry M.L., Souza D.O., and Rocha J.B.T. Diphenyl diselenide and diphenyl ditelluride affect the rat glutamatergic system in vitro and in vivo. Brain Res 906 (2001) 157-163
33. Nogueira C.W., Meotti F.C., Curte E., Pilissão C., Zeni G., and Rocha J.B.T. Investigations into the potential neurotoxicity induced by diselenides in mice and rats. Toxicology 183 (2003) 29-37
34. Nogueira C.W., Quinhones E.B., Jung E.A.C., Zeni G., and Rocha J.B.T. Anti-inflammatory and antinociceptive activity of diphenyl diselenide. Inflamm Res 52 (2003) 56-63
35. Nogueira C.W., Zeni G., and Rocha J.B. Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem Rev 104 (2004) 6255-6285
36. Nutt D.J. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 62 (2001) 22-27
37. Nutt D.J., and Stein D.J. Understanding the neurobiology of comorbidity in anxiety disorders. CNS Spectr 11 (2006) 13-20
38. Paulmier C. Selenium reagents and intermediates in organic synthesis. 1 ed. (1986), Pergamon, Press, Oxford 84-116
39. Posser T., Moretto M.B., Dafre A.L., Farina M., Rocha J.B., Nogueira C.W., et al. Antioxidant effect of diphenyl diselenide against sodium nitroprusside (SNP) induced lipid peroxidation in human platelets and erythrocyte membranes: an in vitro evaluation. Chem Biol Interact 164 (2006) 126-135
40. Rayman M.P. The importance of selenium to human health. Lancet 356 (2000) 233-241
41. Rossato J.L., Ketzer L.A., Centurião F.B., Silva S.J.N., Lüdtke D.S., Zeni G., et al. Antioxidant properties of new chalcogenides against lipid peroxidation in rat brain. Neurochem Res 27 (2002) 297-303
42. A receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. PNAS 3 (2005) 915-920
43. Rudolph U. Identification of molecular substrate for the attenuation of anxiety: a step toward the development of better anti-anxiety drugs. Sci World J 1 (2001) 192-193
44. Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J Psychiatr Res 27 (1993) 97-110
45. Savegnago L., Pinto L.G., Jesse C.R., Alves D., Rocha J.B.T., Nogueira C.W., et al. Antinociceptive properties of diphenyl diselenide: evidence for the mechanism of action. Eur J Pharmacol 555 (2007) 129-138
46. Savegnago L., Jesse C.R., Pinto L.G., Rocha J.B.T., Nogueira C.W., and Zeni G. Monoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats. Prog Neuro-Psychopharmacol Biol Psychiatry 31 (2007) 1261-1269
47. Savegnago L., Jesse C.R., Pinto L.G., Rocha J.B.T., Barancelli D.A., Nogueira C.W., et al. Diphenyl diselenide exerts antidepressant-like and anxiolytic-like effects in mice: involvement of l-arginine-nitric oxide-soluble guanylate cyclase pathway in its antidepressant-like action. Pharmacol Biochem Behav 88 (2008) 418-426
48. Schweizer U., Bräuer A.U., Köhrle J., Nitsch R., and Savaskan N.E. Selenium and brain function: a poorly recognized liaison. Brain Res Rev 45 (2004) 164-178
49. Stutzmann J., Eon B., Darche F., Lucas M., Rataud J., Piot O., et al. Are 5-HT2 antagonists endowed with anxiolytic properties in rodents?. Neurosci Lett 128 (1991) 4-8
50. Ursini F., and Bindoli A. The role of selenium peroxidases in the protection against oxidative damage of membranes. Chem Phys Lipids 44 (1987) 255-276
51. Whiting P.J. GABA-A receptors: a viable target for novel anxiolytics?. Curr Opin Pharmacol 6 (2006) 24-29
52. Wilson S.R., Zucker P.A., Huang R.R.C., and Spector A. Development of synthetic compounds with glutathione peroxidase activity. J Am Chem Soc 111 (1989) 5936-5939
53. Wong M., and Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2 (2001) 343-351
54. Zarrindast M.R., Rostami P., and Sadeghi-Hariri M. GABAA but not GABAB receptor stimulation induces antianxiety profile in rats. Pharmacol Biochem Behav 69 (2001) 9-15
55. Zasso F.B., Gonçales C.E.P., Jung E.A.C., Araldi D., Zeni G., Rocha J.B.T., et al. On the mechanisms involved in antinociception induced by diphenyl diselenide. Environ Toxicol Pharmacol 19 (2005) 283-289
56. Zohar J., and Westenberg H.G. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 403 (2000) 39-49